Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune Inc. demonstrates a strong potential for growth driven by positive clinical trial results and a promising pipeline targeting chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's novel molecular structure suggests significant improvements in drug efficacy and half-life, which positions it advantageously within the competitive landscape of chronic inflammatory diseases. Furthermore, the anticipated success of EVO301 in atopic dermatitis may solidify Evommune's first-mover advantage in IL-18 therapies, thereby extending its revenue streams into multiple high-value indications and enhancing long-term commercial opportunity.

Bears say

Evommune Inc's stock faces a negative outlook primarily due to increased competition threatening the projected market performance of its pipeline products EVO756 and EVO301, which are expected to underperform against peak sales estimates. The company may encounter challenges in achieving market access and adoption, leading to a slower-than-anticipated uptake of its therapies. Additionally, there are concerns about potential medium- to long-term equity dilution risks, compounded by the possibility of faster-than-expected generic erosion and patent challenges affecting market exclusivity.

Evommune Inc (EVMN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 7 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.